People with schizophrenia have roughly two to three times the population risk of type 2 diabetes. Some of that excess is from sedentary lifestyle, smoking, and poverty. A meaningful portion is also from antipsychotic medication itself, which can disrupt glucose regulation through mechanisms that are partly weight-related and partly independent of weight. The FDA acknowledged this in 2003 when it added a class warning to all second-generation antipsychotics for hyperglycemia and diabetes.
Olanzapine and clozapine are the antipsychotics most strongly linked to new-onset diabetes, with risk arising both from weight gain and from direct effects on insulin secretion and sensitivity, and the standard response is regular monitoring plus aggressive metabolic management.
The mechanisms
Antipsychotic-induced diabetes appears to involve several pathways:
- Weight gain → insulin resistance — the largest single contributor
- Direct beta-cell effects — some antipsychotics, especially olanzapine and clozapine, may impair insulin secretion in animal models and short-term human studies
- Altered glucose disposal — independent of weight, possibly via muscarinic M3 antagonism
- Lipid changes — rising triglycerides correlate with insulin resistance
- Reduced physical activity from sedation
Case reports of new-onset diabetes within weeks of starting olanzapine, before significant weight gain, support the idea that the medication can have direct effects on glucose handling.
Risk by medication
- Highest: olanzapine, clozapine
- Moderate: quetiapine, risperidone, paliperidone
- Lower: aripiprazole, lurasidone, ziprasidone, brexpiprazole, cariprazine, lumateperone, asenapine
- First-generation antipsychotics: generally lower diabetes risk than olanzapine or clozapine
Standard monitoring
Recommended baseline plus interval testing for any patient starting an antipsychotic:
- Fasting glucose or HbA1c at baseline
- Repeat at 12 weeks
- Then yearly thereafter
- More often if there is significant weight gain or a family history of diabetes
Diabetes diagnosis follows standard ADA criteria: fasting glucose ≥126 mg/dL on two occasions, HbA1c ≥6.5%, or random glucose ≥200 mg/dL with symptoms. Pre-diabetes is defined as HbA1c 5.7–6.4% or fasting glucose 100–125 mg/dL. Catching pre-diabetes is much more useful than catching established diabetes.
Diabetic ketoacidosis
A small but important subset of patients on olanzapine, clozapine, and (less commonly) other agents have developed new-onset diabetic ketoacidosis (DKA), sometimes without prior known diabetes. DKA is a medical emergency: severe hyperglycemia, ketones, dehydration, fast breathing, abdominal pain, altered mental status. The FDA labels reflect this risk. Patients should know the warning symptoms.
Excessive thirst and urination, blurred vision, confusion, deep rapid breathing, fruity-smelling breath, abdominal pain, or unexplained weight loss while on an antipsychotic — particularly olanzapine or clozapine — can indicate severe hyperglycemia or DKA and warrants immediate evaluation.
What to do if labs are abnormal
1. Treat the diabetes
If criteria are met, the patient gets standard diabetes care — typically metformin first, then additional agents. GLP-1 agonists (semaglutide, liraglutide) have been particularly attractive in this population because they also produce weight loss, which addresses two problems at once. SGLT2 inhibitors are also commonly used.
2. Re-evaluate the antipsychotic
If the antipsychotic was olanzapine or clozapine, switching to a lower-risk agent is often considered, especially if the diabetes appeared shortly after starting. The decision weighs the metabolic benefit of switching against the risk of psychiatric instability. For patients on clozapine for treatment-resistant illness, the calculation usually favours staying on clozapine and managing the diabetes aggressively.
3. Address weight
Concurrent metformin or GLP-1 agonist treatment, behavioural support, and exercise. See our weight gain deep dive.
4. Address related cardiovascular risk
Patients with antipsychotic-induced diabetes should also have lipid panels, blood pressure, and smoking status addressed. The combined cardiovascular risk is the long-term killer.
Why this matters so much
Cardiovascular disease is the leading cause of death in people with schizophrenia, and people with schizophrenia die roughly 15–20 years earlier than the general population on average. A meaningful fraction of that gap comes from poorly managed metabolic disease. Treating antipsychotic-induced diabetes promptly is one of the highest-leverage things a treatment team can do for long-term mortality. The shift over the past decade toward proactive metabolic monitoring, early metformin, and now GLP-1 agonists has begun to close this gap, but unevenly.
Practical principles
- Get the baseline labs before the first dose, not three months in.
- Repeat at 12 weeks. Do not skip this visit.
- If glucose or HbA1c drift up, act early.
- If the antipsychotic is olanzapine or clozapine, consider metformin even before glucose abnormalities appear.
- Coordinate with primary care so diabetes treatment does not fall through the cracks.
The bottom line
Antipsychotic-induced diabetes is preventable, detectable, and treatable. The biggest failures are silent ones — patients who develop diabetes that no one notices because labs were not drawn. The standard of care is clear; the implementation is uneven. Patients who know to ask for their numbers usually get better care than those who do not.
For more, see our schizophrenia and diabetes overview, comorbidity article, and glucose monitoring guide.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.